Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 1/20 | 0.47 |
| ▸ | CASP2 | P42575 | 1/20 | 0.46 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.44 |
| ▸ | CDK1 | P06493 | 1/20 | 0.44 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.44 |
| ▸ | GSK3B | P49841 | 1/20 | 0.44 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.43 |
| ▸ | HBB | P68871 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | SRD5A1 | P18405 | 2/20 | 0.42 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.41 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.41 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.41 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.41 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30683070 | 1.00 | IDO1 (0.47) | IDO1CASP2CCNB2CDK1CCNB1 | |
| SCHEMBL746154 | 0.85 | IDO1 (0.57) | IDO1CASP2CCNB2CDK1CCNB1 | |
| SCHEMBL31711769 | 0.84 | BRD4 (0.41) | CASP2MEN1MAPTALOX15ALOX12 | |
| SCHEMBL17419131 | 0.84 | SRD5A1 (0.55) | CASP2SRD5A1GABRA1GABRG2GABRB3 | |
| SCHEMBL31597788 | 0.84 | SRD5A1 (0.55) | CASP2SRD5A1GABRA1GABRG2GABRB3 | |
| SCHEMBL29134370 | 0.83 | CASP2 (0.42) | IDO1CASP2CCNB2CDK1CCNB1 | |
| SCHEMBL30015775 | 0.83 | CASP2 (0.42) | IDO1CASP2CCNB2CDK1CCNB1 | |
| SCHEMBL22290609 | 0.81 | SRD5A1 (0.46) | CASP2SRD5A1GABRA1GABRG2GABRB3 | |
| SCHEMBL30832142 | 0.81 | SRD5A1 (0.46) | CASP2SRD5A1GABRA1GABRG2GABRB3 | |
| SCHEMBL5986263 | 0.79 | HSD17B10 (0.47) | MEN1KMT2AHSD17B10SRD5A1METAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 119 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4747242-A1 | HETEROCYCLIC INHIBITORS OF IGF-1R FOR TREATMENT OF DISEASE | Horizon Therapeutics Ireland Dac (IE) | 2026-05-27 | — | — | EP | disclosed |
| EP-4081521-B1 | SUBSTITUTED TRICYCLIC COMPOUNDS | LUPIN LTD (IN) | 2025-12-10 | — | — | EP | disclosed |
| US-20250250232-A1 | AZETIDINE DERIVATIVES AND USE THEREOF AS DIPEPTIDYL PEPTIDASE 1 INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2025-08-07 | — | — | US | disclosed |
| US-12365673-B2 | Nitrile derivative that acts as inhibitor of dipeptidyl peptidase 1 and use thereof | HAISCO PHARMACEUTICALS PTE. LTD. (SG) | 2025-07-22 | — | — | US | disclosed |
| WO-2025149545-A1 | HETEROARYLPHENYL ETHER DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2025-07-17 | — | — | WO | disclosed |
| US-20250197407-A1 | TRICYCLIC PHTHALAZINES AND DERIVATIVES AS SOS1 INHIBITORS | U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, AS COLLATERAL TRUSTEE | 2025-06-19 | — | — | US | disclosed |
| US-20250145585-A1 | HETEROCYCLIC INHIBITORS OF IGF-1R FOR TREATMENT OF DISEASE | HORIZON THERAPEUTICS IRELAND DAC (IE) | 2025-05-08 | — | — | US | disclosed |
| US-20250059161-A1 | COMPOUNDS AND METHODS FOR MODULATING STAT3 | VIVIDION THERAPEUTICS, INC. | 2025-02-20 | — | — | US | disclosed |
| EP-4497473-A2 | NITRILE DERIVATIVE THAT ACTS AS INHIBITOR OF DIPEPTIDYL PEPTIDASE 1 AND USE THEREOF | Haisco Pharmaceuticals Pte. Ltd. (SG) | 2025-01-29 | — | — | EP | disclosed |
| EP-4496630-A1 | TRICYCLIC PHTHALAZINES AND DERIVATIVES AS SOS1 INHIBITORS | Jazz Pharmaceuticals Ireland Limited (IE) | 2025-01-29 | — | — | EP | disclosed |
| WO-2010142985-A1 | SUBSTITUTED N-[1-CYANO-2-(PHENYL)ETHYL]PIPERIDIN-2-YLCARBOXMIDE COMPOUNDS 761 | ASTRAZENECA AB (SE) | 2010-12-16 | — | — | WO | disclosed |
| WO-2010142985-A1 | SUBSTITUTED N-[1-CYANO-2-(PHENYL)ETHYL]PIPERIDIN-2-YLCARBOXMIDE COMPOUNDS 761 | ASTRAZENECA AB (SE) | 2010-12-16 | — | — | WO | disclosed |
| WO-2010130794-A1 | 5-PYRIDIN-3-YL-1,3-DIHYDRO-INDOL-2-ON DERIVATIVES AND THEIR USE AS MODULATORS OF ALDOSTERONE SYNTHASE AND/OR CYP11B1 | NOVARTIS AG (CH) | 2010-11-18 | — | — | WO | disclosed |
| WO-2010128324-A1 | SUBSTITUTED 1-CYANOETHYLHETEROCYCLYLCARBOXAMIDE COMPOUNDS 750 | ASTRAZENECA AB (SE) | 2010-11-11 | — | — | WO | disclosed |
| US-20100286118-A1 | SUBSTITUTED 1-CYANOETHYLHETEROCYCLYLCARBOXAMIDE COMPOUNDS 750 | ASTRAZENECA AB (SE) | 2010-11-11 | — | — | US | disclosed |
| EP-2177518-A1 | Organic compounds | Novartis AG (CH) | 2010-04-21 | — | — | EP | disclosed |
| US-20090312304-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2009-12-17 | — | — | US | disclosed |
| US-20090312304-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2009-12-17 | — | — | US | disclosed |
| EP-1833816-B1 | SUBSTITUTED PIPERIDINES AS RENIN INHIBITORS | NOVARTIS AG (CH) | 2009-11-11 | — | — | EP | disclosed |
| WO-2006069788-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2006-07-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286118-A1 | SUBSTITUTED 1-CYANOETHYLHETEROCYCLYLCARBOXAMIDE COMPOUNDS 750 | CNR1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CNR2 | IDO1 3015/4885CASP2 1699/4885CCNB2 110/4885 |
| US-12365673-B2 | Nitrile derivative that acts as inhibitor of dipeptidyl peptidase 1 and use thereof | DPP4, DPP3, DPP9 | IDO1 837/4885CASP2 1825/4885CCNB2 4876/4885 |
| US-20250059161-A1 | COMPOUNDS AND METHODS FOR MODULATING STAT3 | STAT3, JAK2, STAT1 | IDO1 2746/4885CASP2 377/4885CCNB2 2809/4885 |
| US-20250145585-A1 | HETEROCYCLIC INHIBITORS OF IGF-1R FOR TREATMENT OF DISEASE | IGF1R, TSHR, TRHR | IDO1 252/4885CASP2 3339/4885CCNB2 3356/4885 |
| US-20090312304-A1 | ORGANIC COMPOUNDS | REN, ACE, PIGO | IDO1 1993/4885CASP2 1988/4885CCNB2 3712/4885 |
| US-20250250232-A1 | AZETIDINE DERIVATIVES AND USE THEREOF AS DIPEPTIDYL PEPTIDASE 1 INHIBITORS | DPP9, DPP4, DPP3 | IDO1 270/4885CASP2 2404/4885CCNB2 4859/4885 |
| US-20250197407-A1 | TRICYCLIC PHTHALAZINES AND DERIVATIVES AS SOS1 INHIBITORS | SOS1, SOS2, SOST | IDO1 3829/4885CASP2 1596/4885CCNB2 1504/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.